Literature DB >> 982101

Current management of pelvic fractures: a combined surgical-angiographic approach to hemorrhage.

K I Maull, C R Sachatello.   

Abstract

Pelvic retroperitoneal hemorrhage after pelvic fracture accounts for the high mortality and morbidity associated with this injury, a concept confirmed by analysis of 357 patients with pelvic fractures at the University of Kentucky Medical Center. The overall mortality of 9.8% was almost exclusively limited to patients with unstable fractures or crush injuries. The reliability of diagnostic peritoneal lavage in excluding associated intraperitoneal injury and the recognized utility of angiographic methods in identifying the site of bleeding constitute a major advance in management. Prompt angiographic definition of injury to major arterial trunks can lead to early operative intervention for direct vascular control. Bleeding from branches of the hypogastric artery can be managed effectively by clot embolization technic, avoiding operation. Venous bleeding is best treated by tamponade in most cases.

Entities:  

Mesh:

Year:  1976        PMID: 982101     DOI: 10.1097/00007611-197610000-00010

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

1.  Pelvic fracture from major blunt trauma. Outcome is determined by associated injuries.

Authors:  G V Poole; E F Ward; F F Muakkassa; H S Hsu; J A Griswold; R S Rhodes
Journal:  Ann Surg       Date:  1991-06       Impact factor: 12.969

Review 2.  Angiographic embolisation of pelvic ring injuries. Treatment algorithm and review of the literature.

Authors:  Efthimios J Karadimas; Tony Nicolson; Despoina D Kakagia; Stuart J Matthews; Paula J Richards; Peter V Giannoudis
Journal:  Int Orthop       Date:  2011-05-17       Impact factor: 3.075

3.  Definitive control of mortality from severe pelvic fracture.

Authors:  L Flint; G Babikian; M Anders; J Rodriguez; S Steinberg
Journal:  Ann Surg       Date:  1990-06       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.